Q1 EPS Estimates for Voyager Therapeutics Lowered by Wedbush

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Wedbush reduced their Q1 2025 earnings per share estimates for Voyager Therapeutics in a research note issued on Wednesday, March 12th. Wedbush analyst Y. Zhong now expects that the company will post earnings of ($0.37) per share for the quarter, down from their prior estimate of ($0.27). Wedbush currently has a “Outperform” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($0.88) EPS and FY2029 earnings at ($0.87) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. During the same quarter in the prior year, the firm posted $1.25 EPS.

VYGR has been the topic of several other reports. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, March 13th. Finally, Citigroup started coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $14.86.

Voyager Therapeutics Trading Down 0.3 %

VYGR opened at $3.88 on Monday. Voyager Therapeutics has a 1 year low of $3.56 and a 1 year high of $10.66. The stock has a fifty day moving average price of $4.75 and a 200 day moving average price of $5.78. The stock has a market cap of $214.20 million, a price-to-earnings ratio of 5.46 and a beta of 0.99.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Voyager Therapeutics by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company’s stock valued at $18,232,000 after purchasing an additional 29,014 shares during the period. Farallon Capital Management LLC boosted its stake in Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after purchasing an additional 278,700 shares during the period. Dimensional Fund Advisors LP boosted its stake in Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock valued at $7,828,000 after purchasing an additional 275,571 shares during the period. Vestal Point Capital LP boosted its stake in Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock valued at $6,974,000 after purchasing an additional 740,000 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Voyager Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock valued at $6,149,000 after purchasing an additional 4,729 shares during the period. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.